Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.

Nishimura N, Radwan MO, Amano M, Endo S, Fujii E, Hayashi H, Ueno S, Ueno N, Tatetsu H, Hata H, Okamoto Y, Otsuka M, Mitsuya H, Matsuoka M, Okuno Y.

Cancer Sci. 2019 Oct;110(10):3275-3287. doi: 10.1111/cas.14154. Epub 2019 Aug 14.

2.

Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465).

Tatetsu H, Armant M, Wang F, Gao C, Ueno S, Tian X, Federation A, Qi J, Bradner J, Tenen DG, Chai L.

Exp Hematol. 2019 Jul;75:53-63.e11. doi: 10.1016/j.exphem.2019.06.473. Epub 2019 Jun 28.

PMID:
31260717
3.

MUC1/KL-6 expression confers an aggressive phenotype upon myeloma cells.

Endo S, Nishimura N, Kawano Y, Ueno N, Ueno S, Tatetsu H, Komohara Y, Takeya M, Hata H, Mitsuya H, Masao M, Okuno Y.

Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):246-252. doi: 10.1016/j.bbrc.2018.11.016. Epub 2018 Nov 10.

PMID:
30420285
4.

PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.

Ueno N, Nishimura N, Ueno S, Endo S, Tatetsu H, Hirata S, Hata H, Matsuoka M, Mitsuya H, Okuno Y.

Oncogene. 2017 Aug;36(31):4481-4497. doi: 10.1038/onc.2017.79. Epub 2017 Apr 3.

PMID:
28368411
5.

A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivo.

Nishimura N, Endo S, Ueno S, Ueno N, Tatetsu H, Hirata S, Hata H, Komohara Y, Takeya M, Mitsuya H, Okuno Y.

Biochem Biophys Res Commun. 2017 May 13;486(4):916-922. doi: 10.1016/j.bbrc.2017.03.124. Epub 2017 Mar 24.

PMID:
28347818
6.

Targeting SALL4 by entinostat in lung cancer.

Yong KJ, Li A, Ou WB, Hong CK, Zhao W, Wang F, Tatetsu H, Yan B, Qi L, Fletcher JA, Yang H, Soo R, Tenen DG, Chai L.

Oncotarget. 2016 Nov 15;7(46):75425-75440. doi: 10.18632/oncotarget.12251.

7.

Leukemic survival factor SALL4 contributes to defective DNA damage repair.

Wang F, Gao C, Lu J, Tatetsu H, Williams DA, Müller LU, Cui W, Chai L.

Oncogene. 2016 Nov 24;35(47):6087-6095. doi: 10.1038/onc.2016.146. Epub 2016 May 2.

8.

SALL4, the missing link between stem cells, development and cancer.

Tatetsu H, Kong NR, Chong G, Amabile G, Tenen DG, Chai L.

Gene. 2016 Jun 15;584(2):111-9. doi: 10.1016/j.gene.2016.02.019. Epub 2016 Feb 16. Review.

9.

Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex.

Gao C, Dimitrov T, Yong KJ, Tatetsu H, Jeong HW, Luo HR, Bradner JE, Tenen DG, Chai L.

Blood. 2013 Feb 21;121(8):1413-21. doi: 10.1182/blood-2012-04-424275. Epub 2013 Jan 3.

10.

PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.

Yuki H, Ueno S, Tatetsu H, Niiro H, Iino T, Endo S, Kawano Y, Komohara Y, Takeya M, Hata H, Okada S, Watanabe T, Akashi K, Mitsuya H, Okuno Y.

Blood. 2013 Feb 7;121(6):962-70. doi: 10.1182/blood-2012-05-431429. Epub 2012 Dec 4.

PMID:
23212521
11.

Three cases of aggressive natural killer cell leukemia with a lethal hemorrhagic complication.

Okuno Y, Tatetsu H, Nosaka K, Mitsuya H.

J Clin Exp Hematop. 2012;52(2):101-6.

12.

PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.

Ueno S, Tatetsu H, Hata H, Iino T, Niiro H, Akashi K, Tenen DG, Mitsuya H, Okuno Y.

Oncogene. 2009 Nov 19;28(46):4116-25. doi: 10.1038/onc.2009.263. Epub 2009 Sep 14.

13.

Bone marrow large B cell lymphoma bearing cyclin D3 expression: clinical, morphologic, immunophenotypic, and genotypic analyses of seven patients.

Watanuki J, Hatakeyama K, Sonoki T, Tatetsu H, Yoshida K, Fujii S, Mizutani M, Abo T, Kurimoto M, Matsuoka H, Matsuno F, Nakakuma H.

Int J Hematol. 2009 Sep;90(2):217-225. doi: 10.1007/s12185-009-0382-6. Epub 2009 Jul 29.

PMID:
19639271
14.

Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cells.

Uchiba M, Imamura T, Hata H, Tatetsu H, Yonemura Y, Ueda M, Wada Y, Mitsuya H, Ando Y.

Amyloid. 2009;16(2):89-93. doi: 10.1080/13506120902879269.

PMID:
20536401
15.

Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloid.

Kikukawa Y, Okuno Y, Tatetsu H, Nakamura M, Harada N, Ueno S, Kamizaki Y, Mitsuya H, Hata H.

Int J Oncol. 2008 Oct;33(4):807-14.

PMID:
18813795
16.

Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor.

Tatetsu H, Matsuno F, Takatsu N, Miyake H, Hoshino K, Nosaka K, Horikawa K, Hata H, Mitsuya H, Asou N.

Leuk Res. 2009 Jan;33(1):197-200. doi: 10.1016/j.leukres.2008.04.002. Epub 2008 May 12. No abstract available.

PMID:
18472159
17.

Molecular cloning of translocation breakpoint from der(8)t(3;8)(q27;q24) defines juxtaposition of downstream of C-MYC and upstream of BCL6.

Sonoki T, Tatetsu H, Nagasaki A, Hata H.

Int J Hematol. 2007 Aug;86(2):196-8. No abstract available.

PMID:
17875538
18.

Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.

Tatetsu H, Ueno S, Hata H, Yamada Y, Takeya M, Mitsuya H, Tenen DG, Okuno Y.

Cancer Res. 2007 Jun 1;67(11):5328-36.

19.

Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia.

Tatetsu H, Asou N, Nakamura M, Hanaoka N, Matsuno F, Horikawa K, Mitsuya H.

Am J Hematol. 2006 May;81(5):366-9.

20.

Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells.

Nakamura M, Gotoh T, Okuno Y, Tatetsu H, Sonoki T, Uneda S, Mori M, Mitsuya H, Hata H.

Leuk Lymphoma. 2006 Mar;47(3):531-9.

PMID:
16396777
21.

Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.

Tatetsu H, Okuno Y, Nakamura M, Matsuno F, Sonoki T, Taniguchi I, Uneda S, Umezawa K, Mitsuya H, Hata H.

Mol Cancer Ther. 2005 Jul;4(7):1114-20.

22.

[Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine].

Tatetsu H, Asou N, Nakamura M, Koh Y, Tajiri T, Matsuno F, Horikawa K, Yonemura Y, Mitsuya H.

Rinsho Ketsueki. 2003 Jul;44(7):471-3. Japanese.

PMID:
12931567

Supplemental Content

Loading ...
Support Center